Analyzing Q32 Bio (QTTB) and The Competition

Q32 Bio (NASDAQ:QTTB) is one of 1,000 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Q32 Bio to similar businesses based on the strength of its valuation, profitability, institutional ownership, earnings, risk, analyst recommendations and dividends.

Earnings and Valuation

This table compares Q32 Bio and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Q32 Bio	-$6.65 million	-$112.96 million	-0.73
Q32 Bio Competitors	$1.70 billion	$146.87 million	-1.40

Q32 Bio’s competitors have higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Q32 Bio has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Q32 Bio’s competitors have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.

Institutional and Insider Ownership

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 16.1% of Q32 Bio shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Q32 Bio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0	0	2	0	3.00
Q32 Bio Competitors	6384	18716	44590	917	2.57

Q32 Bio presently has a consensus target price of $47.50, suggesting a potential upside of 85.62%. As a group, “Pharmaceutical preparations” companies have a potential upside of 83.80%. Given Q32 Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Q32 Bio is more favorable than its competitors.

Profitability

This table compares Q32 Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	-102.52%	-74.91%
Q32 Bio Competitors	-2,459.06%	-249.83%	-30.60%

Summary

Q32 Bio beats its competitors on 7 of the 13 factors compared.

About Q32 Bio

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.